Imkongyanger, Kikoleho Richa, Tsenbeni N Lotha, Ketiyala Ao, Lemzila Rudithongru, Vevosa Nakro, Vimha Ritse, Nima D Namsa, Pranay Punj Pankaj, Upasana Bora Sinha, Latonglila Jamir
{"title":"Sustainable Synthesis of Guanidine Derivatives and Computational Assessment of their Antidiabetic Efficacy.","authors":"Imkongyanger, Kikoleho Richa, Tsenbeni N Lotha, Ketiyala Ao, Lemzila Rudithongru, Vevosa Nakro, Vimha Ritse, Nima D Namsa, Pranay Punj Pankaj, Upasana Bora Sinha, Latonglila Jamir","doi":"10.2174/0118715303287962240621053459","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Type 2 Diabetes Mellitus (T2DM) represents a significant and pressing worldwide health concern, necessitating the quest for enhanced antidiabetic pharmaceuticals. Guanidine derivatives, notably metformin and buformin, have emerged as pivotal therapeutic agents for T2DM management.</p><p><strong>Aims: </strong>The present study introduces an efficient one-pot synthesis method for the production of symmetrical guanidine compounds.</p><p><strong>Methods: </strong>This synthesis involves the reaction of isothiocyanates with secondary amines, employing an environmentally friendly and recyclable reagent, tetrabutylphosphonium tribromide (TBPTB).</p><p><strong>Results: </strong>A comprehensive assessment of the biological activity of the synthesized guanidine compounds, specifically in the context of T2DM, has been rigorously conducted.</p><p><strong>Conclusion: </strong>Additionally, computational analyses have unveiled their substantial potential as promising antidiabetic agents. Results highlight the relevance of these compounds in the ongoing pursuit of novel therapeutic solutions for T2DM.</p>.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715303287962240621053459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Type 2 Diabetes Mellitus (T2DM) represents a significant and pressing worldwide health concern, necessitating the quest for enhanced antidiabetic pharmaceuticals. Guanidine derivatives, notably metformin and buformin, have emerged as pivotal therapeutic agents for T2DM management.
Aims: The present study introduces an efficient one-pot synthesis method for the production of symmetrical guanidine compounds.
Methods: This synthesis involves the reaction of isothiocyanates with secondary amines, employing an environmentally friendly and recyclable reagent, tetrabutylphosphonium tribromide (TBPTB).
Results: A comprehensive assessment of the biological activity of the synthesized guanidine compounds, specifically in the context of T2DM, has been rigorously conducted.
Conclusion: Additionally, computational analyses have unveiled their substantial potential as promising antidiabetic agents. Results highlight the relevance of these compounds in the ongoing pursuit of novel therapeutic solutions for T2DM.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
